Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described. BRCA1 and BRCA2 (Breast Cancer) proteins are involved in homologous recombination repair (HRR), which requires a homologous chromosome or sister chromatid as a template to faithfully repair DNA double-strand breaks. The small-molecule NAD+ mimetics, olaparib, niraparib, rucaparib, veliparib, and talazoparib, inhibit the catalytic activity of PARP-1 and PARP-2 and are currently being studied in later-stage clinical trials. PARP inhibitor clinical trials have predominantly focused on patients with breast and ovarian cancer with deleterious germline BRCA1 and BRCA2 mutations (gBRCA1/2+) but are now expanding to include cancers with known, suspected, or morelikely-than-not defects in homologous recombination repair. In ovarian cancer, this group also includes women whose cancers are responsive to platinum therapy. Olaparib was FDA-approved in January 2018 for the treatment of gBRCA1/2+ metastatic breast cancers. gBRCA1+ predisposes women to develop triple-negative breast cancers, while women with gBRCA2+ tend to develop hormone-receptor-positive, human epidermal growth factor receptor 2 negative breast cancers. Although PARP inhibitor monotherapy strategies seem most effective in cancers with homologous recombination repair defects, combination strategies may allow expansion into a wider range of cancers. By interfering with DNA repair, PARP inhibitors essentially sensitize cells to DNA-damaging chemotherapies and radiation therapy. Certainly, one could also consider expanding the utility of PARP inhibitors beyond gBRCA1/2+ cancers by causing DNA damage with cytotoxic agents in the presence of a DNA repair inhibitor. Unfortunately, in numerous phase I clinical trials utilizing a combination of cytotoxic chemotherapy at standard doses with dose-escalation of PARP inhibitors, there has generally been failure to reach monotherapy dosages of PARP inhibitors due to myelosuppressive toxicities. Strategies utilizing angiogenesis inhibitors and immune checkpoint inhibitors are generally not hindered by additive toxicities, though the utility of combining PARP inhibitors with treatments that have not been particularly effective in breast cancers somewhat tempers enthusiasm. Finally, there are combination strategies that may serve to mitigate resistance to PARP inhibitors, namely, upregulation of the intracellular PhosphoInositide-3-kinase, AK thymoma (protein kinase B), mechanistic target of rapamycin (PI3K-AKT-mTOR) pathway, or perhaps are more simply meant to interfere with a cell growth pathway heavily implicated in breast cancers while administering relatively well-tolerated PARP inhibitor therapy.
Introduction
In the care of oncology patients, poly-ADP-ribose polymerase (PARP) inhibitors are best known as a semitargeted treatment for BRCA1-and BRCA2-associated ovarian and breast cancers, but a broader understanding of PARP biology has spurred interest in expanding their clinical utility (see Figure 1) . Using NAD+ as a substrate, PARP enzymes catalyze the addition of linear and branching chains of ADP-ribose to aspartic acid, glutamic acid, and/or lysine amino acids on acceptor proteins in a process termed poly-ADP-ribose-ylation ('PARylation'). 1 Seventeen PARP enzymes have been discovered, with their functionalities primarily determined by their target-binding domains, cellular compartment localization signals, and tertiary structures. 1,2 PARP-1 and PARP-2 localize to the nucleus and undergo conformational changes to become catalytically activated upon binding to exposed DNA. They effectively act as sensors of DNA damage -including single-strand and doublestrand DNA breaks, DNA supercoils, DNA crosslinks, and stalled replication forks -and facilitate DNA repair processes at the
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REVIEW -PARP inhibitors for breast cancer drugsincontext.com site of damage. 3 PARP-1 self-PARylates its automodification domain to release itself from DNA, a process that is inhibited in the presence of PARP inhibitors (PARPi) and has been termed 'PARP-trapping.' 2, 4, 5 PARP-1 and PARP-2 are the primary targets of PARPi in clinical development due to their roles in the repair of DNA, but the understanding of PARP-1's role in DNA repair has shifted over time. PARP-1 was originally described as part of the base excision repair (BER) pathway based on genetic studies, but PARP-1 and PARylation are now known to have much wider-reaching roles in all major DNA repair pathways. PARP-1 has been implicated in chromatin relaxation by histone modification, recruitment of repair proteins to the site of DNA damage, inhibition of transcription through PARylation of Ribonucleic acid (RNA) polymerases I and II, cell cycle arrest, and apoptosis. 2, [6] [7] [8] During apoptosis, caspase-mediated cleavage of PARP-1 releases the N-terminal nuclear localization signal and DNA-binding domains from the C-terminal catalytic and auto-PARylation domains, uncoupling DNA repair and DNA binding ( Figure 2 ). 2, 3, 9 The N-terminal fragment of 'cleaved PARP' binds DNA in a natural form of PARP-trapping to prevent DNA repair, replication, and transcription in a dying cell. 9 PARPi are molecular mimics of nicotinamide that compete with NAD+ at the catalytic site of PARP enzymes and thus prevent PARylation. Their specificity for one or more of the PARP enzymes varies, as does their potency. [10] [11] [12] By interfering with its ability to PARylate itself but not its ability to bind DNA, PARP-1 inhibitors also result in PARP-trapping. 4, 5 In addition to interfering with DNA repair, transcription, and replication, PARP-trapping can itself cause lethal DNA double-strand breaks during S-phase by collapse of stalled replication forks. 13 The most well-represented PARPi in clinical trials include olaparib, veliparib, niraparib, rucaparib, and talazoparib. 14-18 Although iniparib was found to inhibit PARP-1 function in vitro and was tested in clinical trials, it was eventually found to bind to PARP-1's zinc-finger domain rather than the catalytic domain and is no longer considered to be a PARP inhibitor for the purposes of clinical trial research. 19, 20 Early clinical trials were designed to use PARPi in patients with germline BRCA1 or BRCA2 mutations with breast and ovarian cancers deficient in DNA repair by HRR due to acquired loss of BRCA1/2 heterozygosity. [21] [22] [23] With an understanding of PARP as a BER enzyme, the PARPi were thought to contribute to a type of 'synthetic lethality' by PARP-1 and PARP-2 recognize DNA damage, including single-strand and double-strand DNA breaks, DNA crosslinks, supercoils, and stalled replication forks. Upon binding to DNA, PARP-1 and PARP-2 become catalytically active, utilizing nicotinamide as a substrate to add ADP-ribose chains to target proteins in a process termed 'PARylation.' PARylation of histones H2B and H1 relaxes the chromatin to allow access to DNA for repair, the G2/M checkpoint is activated to allow time to repair DNA, DNA repair proteins are recruited to the site of damage, and transcription is temporarily halted via PARylation of RNA Pol I and RNA Pol II. PARP-1 also has roles to play in cell death if DNA cannot be repaired, both as an active participant in apoptosis and indirectly by draining the cell of its nicotinamide resources, which is necessary for normal cell respiration. ATM, Ataxia telangiectasia mutated serine/threonine kinase; dsDNA, double-stranded DNA; NAD+, nicotinamide; PARP-1, poly-ADP-ribosyl polymerase 1; PARylation, poly(ADP-ribose)ylation; ssDNA, single-stranded DNA. ISSN: 1740-4398 REVIEW -PARP inhibitors for breast cancer drugsincontext.com
PARP inhibitor monotherapy
Olaparib, rucaparib, and niraparib are approved for use in ovarian cancer as monotherapy. [104] [105] [106] [107] [108] [109] [110] Efficacy data for PARP inhibitor monotherapy in breast cancer patients primarily come from early stage clinical trials. However, two phase III studies evaluating single agent PARP inhibition (olaparib and talazoparib) in advanced breast cancer have recently been reported, resulting in the first regulatory approval of a PARP inhibitor for breast cancer. The results of monotherapy studies are reviewed later.
Olaparib
In 2009, Fong et al. published the results of a phase I clinical trial (NCT00516373) of olaparib in patients with advanced solid tumors followed by an expansion cohort enriched for gBRCA1/2+ patients with ovarian and breast cancers. 27 One of the nine breast cancer patients -gBRCA2+ with extensive pulmonary metastases and progression on anthracycline-based chemotherapy -had a complete response (CR) that lasted over 60 months. An additional 3/9 breast cancer patients, one gBRCA2+ and two BRCA wild-type (BRCA-wt), had stable disease (SD) for 4 months or more.
The nature of phase I clinical trials with cytotoxic therapies is to dose-escalate to a maximum tolerated dose (MTD) based on dose-limiting toxicities (DLTs) to establish a recommended phase II dose (RP2D). The minimal effective dose is not usually determined, though in clinical practice cytotoxic therapies are often dose-reduced from standard doses according to an which inhibition of two DNA repair pathways contributes to preferential cell kill in HRR-deficient cancerous cells over normal cells. As knowledge of PARP-1's roles and the mechanisms by which PARPi exert their efficacy has expanded, an updated basic science understanding also considers PARPi as 1) interfering with the identification of DNA damage and multiple types of repair, 2) predominantly exerting their effects during S-phase when dependence on PARP-1 and PARP-2 is highest, DNA is exposed for replication, and HRR is preferred over nonhomologous end-joining (NHEJ) for repair of DNA double-strand breaks, and 3 likely to be strongly dose-dependent if PARP-trapping is a clinically relevant in vivo mechanism. 1, [4] [5] [6] 8 These concepts drive some of the PARPi combination trials, as is most evident in the plethora of combination clinical trials for ovarian cancer. 24 Current PARPi clinical trials registered with the National Institutes of Health's United States National Library of Medicine in ClinicalTrials.gov which include patients with breast cancer are listed in Table 1 , which is headed by monotherapy trials followed by combination trials, organized by type of combination (e.g. PARPi + chemotherapy) and clinical trial phase from I to III within each category, and includes trial characteristics, patient population (with gBRCA1/2 bolded if a requirement for a particular trial), trial interventions with the PARPi bolded for easy reference, and outcome measures. Search terms were 'breast cancer' and 'PARP.' Data for individual trials were garnered using the Google and Google Scholar search engines to identify published manuscripts and oncology conference abstracts. events using CTCAE; DM, double masking; DOR, duration of response = time from initial response to first documented tumor progression; gBRCA1/2+, germline-mutated BRCA1 or BRCA2; HER2, human epidermal growth factor; HGSOC, high-grade serous ovarian cancer; HRD, homologous recombination deficiency (as defined by a deleterious mutation in BRCA1, BRCA2, PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, or FANC genes or by a high score on Myriad's HRD assay); irRC, ImmuneRelated Response Criteria = rules defining tumor response, stabilization, or progression for immuno-oncology drugs, which can result in an inflammatory response that appears to be progression; LRFS, local recurrence-free survival = time from enrollment to first local recurrence or death from all causes; Met, metastatic disease; MTD, maximum tolerated dose = one dose level below the highest dose at which 1/3 of the patients at that dose level experience a dose-limiting toxicity as defined by NCI CTCAE; NCI, National Cancer Institute; Neoadj, neoadjuvant = pre-operative chemotherapy; NR, nonrandomized; O, open label; OBD, optimal biologic dose = dose of complete PARP inhibition; ORR, objective response rate = CR + PR; OS, overall survival = time from study enrollment until death from all causes; P, parallel assignment; pCR, pathological complete response = no tumor remaining in breast or lymph nodes after neoadjuvant therapy as determined by pathological evaluation; PD, pharmacodynamics = drug effect on physiology; PFS, progression-free survival = time from study enrollment to determination of tumor progression or death due to any cause; PFS2, progression-free survival 2 = time from first PFS to second PFS or death; PK, pharmacokinetics = study of the absorption, bodily distribution, metabolism, and excretion of drugs; po, per os (by mouth); PR, partial response rate = proportion of patients with favorable but incomplete response of a predefined amount for a predefined minimum time period; QoL, quality of life = impact of health status on physical, mental, emotional, social functioning; R, randomized; RadR, radiological response rate; RCB, residual cancer burden = pathological diagnosis of residual cancer burden after neoadjuvant chemotherapy at time of surgical resection; RECIST, Response Evaluation Criteria in Solid Tumors = rules defining tumor response, stabilization, or progression for antineoplastic agents; RFS, relapse-free survival; RP2D, recommended phase 2 dose = highest oncology drug dose with acceptable toxicity, usually defined in reference to DLT and MTD established in phase I clinical trials; S, sequential assignment; SD, stable disease rate = proportion of patients without disease shrinkage or progression by RECIST criteria; SG, single group; S/T, safety and tolerability = number and grade of adverse events; TCR, therapy completion rate; TFST, time to first subsequent therapy = time from enrollment to the first subsequent therapy start date or death date; TKI, tyrosine kinase inhibitor; TNBC, triple-negative breast cancer; TRR, tumor response rate = CR + PR; TSST, time to second subsequent therapy = time from enrollment to the second subsequent therapy start date or death date; TTD, time to treatment discontinuation = time from enrollment to treatment discontinuation for any reason; TTF, time to treatment failure = time from enrollment to documentation of progression, unacceptable toxicity, or patient refusal to continue participation; TTP, time to progression = time from study enrollment to determination of tumor progression; TTR, time to tumor response; TTSC, time to second cancer; VEGFR, Vascular endothelial growth factor receptor; X, crossover study; yo, years old. 
Talazoparib
In phase I/II trial NCT01286987 with talazoparib, 50% (7/14) of gBRCA1/2+ breast cancer patients had an objective response at the 1.0 mg p.o. daily dose. 35 The phase II ABRAZO trial (NCT02034916) investigated talazoparib in patients with gBRCA1/2+ locally advanced or metastatic breast cancers with or without prior exposure to platinum agents. 46 Those enrolled in the platinum-exposed arm were required to have had a documented PR or CR and could not have had progression of their disease on a platinum agent. Those who had not been exposed to platinum were required to have had two or more nonplatinum regimens in the metastatic setting. The primary outcome measure was ORR with CBR, PFS, and OS among the secondary outcome measures. Response rates to talazoparib were higher in patients who had not had prior platinum exposure, suggesting some degree of cross-resistance. 112 Patients were randomly assigned in a 2:1 ratio to talazoparib (n=287) or chemotherapy (n=144). The primary endpoint was PFS (assessed by BICR) with secondary endpoints being safety, OS, ORR, CBR at 24 weeks, and quality of life measurements. mPFS was 8.6 individual patient's toxicities. It could be argued that PARP inhibitors are a novel cytotoxic therapy, as they do essentially perpetuate DNA damage and have myelosuppression as the DLT. Olaparib was originally FDA-approved at a dosage of 400 mg by mouth twice daily, which required patients to take eight 50 mg capsules twice a day. The phase II trial ICEBERG 1 (NCT00494234) investigated dosage levels of 100 mg by mouth twice daily (n=27) compared with 400 mg by mouth twice daily (n=27) in women with gBRCA1/2 mutations with advanced breast cancers after a minimum of one cytotoxic regimen in the metastatic setting. The 100 mg dosage was grossly inferior in terms of median progression free survival (mPFS), overall response rate (ORR), and clinical benefit rate (CBR). 36 weekly × 3 weeks of a 28-day cycle, after 7/9 women in cohort 1 developed neutropenia (4/9 grade 3 or 4) with 8/9 requiring dose delay or reduction of paclitaxel. 73 After implementation of neutropenia management with G-CSF, cohort 2 (n=10) fared better, with 4/10 developing neutropenia (2/10 grade 3 or 4) and fewer paclitaxel dose reductions.
In the ongoing phase II neoadjuvant I-SPY 2 trial (NCT01042379), breast cancer patients with operable stage II-III or stage IV with solely supraclavicular lymph node involvement ('regional stage IV') and tumors ≥ 2.5 cm are randomized to one of many experimental arms with a standard-of-care control arm of paclitaxel, 80 mg/m 2 weekly × 12 weeks (T), followed by doxorubicin + cyclophosphamide (AC) ×4 cycles. 77 The primary outcome measure is probability of pathologic complete response (pCR) over standard neoadjuvant therapy. I-SPY 2 included an experimental arm with PARP inhibitor veliparib, which was dosed at 50 mg p.o. b.i.d. continuously in conjunction with paclitaxel + carboplatin AUC6 on day 1 of a 21-day cycle (TCV) and followed by AC ×4 cycles. The estimated pCR rate in TNBC of TCV ⇒ AC (n=72) was estimated to be 51% (95% Bayesian probability interval 36-66%) compared to 26% in the T ⇒ AC arm (n=44) (95% Bayesian probability interval 9-43%). The predicted probability of success of TCV ⇒ AC in TNBC patients in a phase III trial was estimated to be 88%. 
Niraparib
In the phase I trial NCT00749502 evaluating niraparib in patients with advanced malignancies, the ORR was 2 of 4 gBRCA1/2+ breast cancer patients with one achieving PR at 150 mg/day for 132 days and the second with PR at 210 mg/day for 133 days. The RP2D was declared at 300 mg p.o. daily. 26 The BRAVO study (NCT01905592) is a randomized phase III clinical trial investigating niraparib, 300 mg p.o. daily, compared to physician's choice of chemotherapy with a primary outcome measure of PFS.
Rucaparib
Rucaparib has been predominantly studied in ovarian cancer, but the phase II 'RUBY' trial (NCT02505048) is currently recruiting patients with metastatic gBRCA-wt, HER2-negative breast cancers with a 'BRCAness' phenotype as determined by Clovis genomic signature testing or BRCA1/2 somatic mutation. 115 
Veliparib
Veliparib was studied in cancers associated with gBRCA1/2+, ovarian cancers, or basal-like HER2-negative breast cancers in NCT0089736. 31,116 Of the 52 BRCA+ patients (13 with breast cancer) evaluated for response (all dose levels included), the ORR was 23%, and the CBR was 58%. 32 Myelosuppression is the primary DLT for PARPi, which has made combination of PARPi with cytotoxic chemotherapies problematic (see Table 2 ).
The majority of phase I clinical trials using chemotherapyPARPi combination approaches has understandably prioritized ISSN: 1740-4398 REVIEW -PARP inhibitors for breast cancer drugsincontext.com AEs, adverse events as defined by the Common Terminology Criteria for Adverse Events (CTCAE); AUC, area under the curve; bid, bis in die (twice a day); carbo, carboplatin; CBR, clinical benefit rate = CR + PR + SD; cis, cisplatin; CR, complete response rate = proportion of patients with no measurable disease; DLT, dose-limiting toxicity = drug-related grade 3-5 adverse events using CTCAE; DOR, duration of response = time from initial response to first documented tumor progression; gBRCA1/2+, germline-mutated BRCA1 or BRCA2; Gr, grade as defined by CTCAE; HER2-, HER2 negative; HR+, hormone receptor positive; IV, intravenous; MTD, maximum tolerated dose = one dose level below the highest dose at which 1/3 of the patients at that dose level experience a dose-limiting toxicity as defined by CTCAE; n, number of patients; N/A, not applicable/available; ORR, objective response rate = CR + PR; OS, overall survival = time from study enrollment until death from all causes; pem, pemetrexed; PFS, progression-free survival = time from study enrollment to determination of tumor progression or death due to any cause; po, per os (by mouth); PR, partial response rate = proportion of patients with favorable but incomplete response of a predefined amount for a predefined minimum time period; RECIST, Response Evaluation Criteria in Solid Tumors; RP2D, recommended phase 2 dose = highest oncology drug dose with acceptable toxicity, usually defined in reference to DLT and MTD established in phase I clinical trials; SD, stable disease rate = proportion of patients without disease shrinkage or progression by RECIST criteria; TNBC, triple-negative breast cancer; wt, wild-type gene. 
Angiogenesis, heat-shock protein inhibitors, and immune checkpoint inhibitors
Angiogenesis inhibitors and immune checkpoint inhibitors have thus far not reliably been shown to be of benefit in the treatment of breast cancer, and so there are no current FDA-approved indications for their use in breast cancer. 132 The combination of angiogenesis inhibitors and/or immune checkpoint inhibitors with PARP inhibitors will likely be safe due to nonoverlapping toxicities, and it might be expected that PARP inhibitors could be used at full monotherapy dosages.
Biologically, it has been hypothesized that hypoxia induces down-regulation of HRR proteins BRCA1 and RAD51 and induces a BRCA-like state that could sensitize cells to PARP inhibitors. 133 
Conclusions
The recent FDA approval of olaparib has been a muchwelcomed expansion of therapeutic options for metastatic gBRCA1/2+ breast cancer patients. If PARPi approvals for breast cancer are to follow the same path as those for ovarian cancer, we are likely to see the approval of additional PARP inhibitors in the near future. To date, there is no data demonstrating an OS benefit for PARP inhibitors in breast cancer patients, though to be fair, none of the studies discussed in this manuscript has been powered to detect OS. In the metastatic setting, OS data are difficult to interpret, as treatment options are numerous and patients are likely to be treated with a series of therapies for disease control. The phase III trial OlympiA is powered to assess OS in patients with HER2-negative breast cancer with gBRCA1/2 mutations treated with olaparib in the adjuvant setting; data are expected in 2020.
Active PARPi monotherapy phase I and II trials hint at a willingness to explore their use beyond patients with deleterious germline BRCA1/2 mutations to cancers with defects in homologous recombination repair, either germline or acquired, as well as in TNBC. Several academic and commercial institutions are developing assays to test tumor tissue for a BRCA-like phenotype, loosely defined as homologous recombination repair deficiency, and thus to expand the number of patients who could be offered PARP inhibitors. 26, 27 Combination strategies could also potentially expand the role of PARP inhibitors beyond cancers with homologous recombination repair defects, though it will take time to understand how best to use them to full effect while minimizing toxicities. The diversity of currently active early phase combination clinical trials is a fascinating reflection of a rapidly growing understanding of DNA repair, PARP inhibitor resistance mechanisms, and cancer biology. In the details and designs of the clinical trials discussed herein, there are clues that platinum sensitivity predicts response to PARP inhibitors, PARP inhibitors may be useful radiosensitizers and chemosensitizers, induction of 'BRCAness' is being explored for therapeutic exploitation, and that intermittent dosing and G-CSF support are feasible tactics to mitigate myelosuppressive toxicities of PARP inhibitors in the same way as for cytotoxic chemotherapies. PARP inhibitors remain a very active area of research, to the benefit of our future patients.
trials combining PARP inhibitors with VEGFR TKIs are currently recruiting patients with advanced or metastatic TNBC in the second-line-or-beyond setting: NCT03075462 (PARP inhibitor fluzoparib + VEGFR inhibitor apatinib), NCT02484404 (olaparib + VEGFR inhibitor cediranib), and NCT02498613 (olaparib + cediranib). 84, 86, 87 NCT02484404 also includes an arm with olaparib + cediranib + PDL1 inhibitor durvalumab.
Induction of a BRCA-like phenotype is also the rationale behind the phase I dose-escalation clinical trial NCT02898207, which combines olaparib with heat-shock protein 90 (HSP90) inhibitor onalespib for patients with metastatic TNBC. 88 HSP90 is a chaperone protein that facilitates folding and stabilization of BRCA1 (among many other proteins). 136 Preclinical data suggest that stabilization of deleteriously mutated BRCA1 could be a mechanism of resistance to platinum agents and PARP inhibitors. 137 There [92] [93] [94] Intracellular signaling
The intracellular phosphorylation cascades of the Rat sarcoma, rapidly accelerated fibrosarcoma, extracellular signal-regulated kinases (RAS-RAF-MEK-ERK) and PI3K-AKT-mTOR pathways have been implicated in the proliferation, survival, and metastatic potential of numerous types of cancer, thus driving development of small-molecule inhibitors targeting these pathways. 139, 140 PI3K, AKT, and mTOR inhibitors are of special interest in clinical trials for breast cancer in particular, as enhanced signaling through the PI3K-AKT-mTOR pathway is thought to represent a major mechanism of resistance to therapies targeting the estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). 141 There are dozens of inhibitors of the PI3K-AKT-mTOR pathway in development and a wide array of combination clinical trials in early and late stages, though FDA-approvedindications for treatment of breast cancer with PI3K-AKT-mTOR inhibitors has been thus far limited to mTOR inhibitor everolimus in combination with exemestane after failure of letrozole or anastrozole for advanced hormone-receptor-positive (HR+), HER2-negative breast cancer based on BOLERO-2. 142, 143 Preclinical data suggest that upregulation of the PI3K-AKTmTOR pathway may contribute to PARP inhibitor resistance
